Comparing One vs. Two Antibiotics and Treatment Lengths for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

What this Trial Is About

Researchers are evaluating different antibiotic treatments for patients in intensive care units who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. The study compares the effects of using one antibiotic monotherapy versus a combination of two antibiotics, as well as shorter 7 days versus longer 14 days treatment durations. This research also looks at how resistant the bacteria are to antibiotics and how often pneumonia recurs in these patients. The study involves observing patients who meet specific criteria without assigning new treatments directly. It focuses on the antibiotic strategies already being used, comparing their impact on patient survival. The main measurement is survival within 28 days based on the treatment strategy applied. There are no additional experimental interventions since this is an observational study. Participants will be adult patients who were hospitalized in a medical intensive care unit between January 1, 2018, and December 31, 2023, who were intubated and mechanically ventilated with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia. The research team collects data on patient outcomes, antibiotic resistance, and pneumonia recurrence. The study aims to understand which antibiotic approaches may support better survival in this group.

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients